Law360 Rising Star Profile: Lieff Cabraser’s Lin Chan

Law360 Rising Star Profile: Lieff Cabraser’s Lin Chan

Law360 has published an in-depth profile of Lieff Cabraser partner Lin Y. Chan, named a Law360 Rising Star for 2017 for Competition. The profile highlights Ms. Chan’s biggest case to date (illegal non-compete agreements over the blockbuster antibiotic Cipro), where she gets her motivation, how she became a competition and antitrust attorney, and the advice she would give to young attorneys striving to be successful in the law. [Read more…]

Law360 Names Lin Chan and Jason Lichtman Rising Stars for 2017

Law360 Names Lin Chan and Jason Lichtman Rising Stars for 2017

We are delighted to announce that Law360 has selected two Lieff Cabraser attorneys as Rising Stars for the year 2017. Lieff Cabraser partner Lin Y. Chan has been selected as one of Law360’s Competition Rising Stars for 2017, and Jason L. Lichtman has been selected as a Consumer Protection Rising Star for 2017. [Read more…]

Why Drug Prices Skyrocket Despite Market Competition

Pharmacy

The LA Times has published an excellent piece on the skyrocketing costs of U.S. prescription drugs despite marketplace competition. The absence of competition for a good or service traditionally provides fertile ground for cost escalation and price-gouging, classic greedy anticompetitive behavior, but the Times’ article explores the prevalence of continuing drug cost escalations in the U.S. even where competition does exist. [Read more…]